Invatec gains access to US market with ev3 deal:
This article was originally published in Clinica
Italian company Invatec has appointed Plymouth, Minnesota-based ev3 as exclusive distributor of its endovascular products in the US. The deal represents Brescia-based company's entry into this significant market for the first time. Invatec will also team up with ev3 to commercialise Invatec's new technology aimed at the embolic protection and thrombectomy markets. ev3, a young, privately-held company involved in developing endovascular technologies, will see its product line expand with this new alliance, particularly in the areas of peripheral angioplasty balloon catheters, balloon-expandable and self-expanding stent systems and guidewires.
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.